{"title":"A Case of Immune Aplastic Anemia during Combined Treatment with Atezolizumab and Chemotherapy for Non-Small Cell Lung Cancer.","authors":"Satoru Matsuki, Namiko Taniuchi, Naoko Okada, Junpei Sato, Nobuhiko Nishijima, Koichiro Kamio, Norio Motoda, Muneo Okamoto, Masahiro Seike, Arata Azuma","doi":"10.1272/jnms.JNMS.2024_91-302","DOIUrl":null,"url":null,"abstract":"<p><p>Immune check point inhibitors (ICIs) have durable antitumor effects. However, autoimmune toxicities, termed immune-related adverse events, occur in some patients. We report a case of severe immune aplastic anemia (AA) in a patient with non-small cell lung cancer who was receiving atezolizumab with bevacizumab/carboplatin/paclitaxel. Although the cancer has not recurred, his bone marrow is depleted and he did not respond to immunosuppressive therapy. He has survived for 1.5 years with blood transfusions and infection control. Immune AA associated with ICIs is rare, and a treatment has not yet been established. This case report provides information on the management and treatment response of patients with AA caused by ICIs. Further studies should investigate the mechanism and pathogenesis of immune AA caused by ICIs.</p>","PeriodicalId":56076,"journal":{"name":"Journal of Nippon Medical School","volume":"91 3","pages":"339-346"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nippon Medical School","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1272/jnms.JNMS.2024_91-302","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Immune check point inhibitors (ICIs) have durable antitumor effects. However, autoimmune toxicities, termed immune-related adverse events, occur in some patients. We report a case of severe immune aplastic anemia (AA) in a patient with non-small cell lung cancer who was receiving atezolizumab with bevacizumab/carboplatin/paclitaxel. Although the cancer has not recurred, his bone marrow is depleted and he did not respond to immunosuppressive therapy. He has survived for 1.5 years with blood transfusions and infection control. Immune AA associated with ICIs is rare, and a treatment has not yet been established. This case report provides information on the management and treatment response of patients with AA caused by ICIs. Further studies should investigate the mechanism and pathogenesis of immune AA caused by ICIs.
免疫检查点抑制剂（ICIs）具有持久的抗肿瘤效果。然而，一些患者会出现自身免疫毒性，即免疫相关不良事件。我们报告了一例严重免疫性再生障碍性贫血（AA）病例，患者患有非小细胞肺癌，正在接受阿特珠单抗联合贝伐单抗/卡铂/紫杉醇治疗。虽然癌症没有复发，但他的骨髓已经枯竭，而且对免疫抑制疗法没有反应。通过输血和感染控制，他已存活了 1.5 年。与 ICIs 相关的免疫 AA 非常罕见，治疗方法尚未确定。本病例报告提供了有关 ICIs 引起的 AA 患者的管理和治疗反应的信息。进一步的研究应探讨 ICIs 引起的免疫性 AA 的机制和发病机理。
期刊介绍：
The international effort to understand, treat and control disease involve clinicians and researchers from many medical and biological science disciplines. The Journal of Nippon Medical School (JNMS) is the official journal of the Medical Association of Nippon Medical School and is dedicated to furthering international exchange of medical science experience and opinion. It provides an international forum for researchers in the fields of bascic and clinical medicine to introduce, discuss and exchange thier novel achievements in biomedical science and a platform for the worldwide dissemination and steering of biomedical knowledge for the benefit of human health and welfare. Properly reasoned discussions disciplined by appropriate references to existing bodies of knowledge or aimed at motivating the creation of such knowledge is the aim of the journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
